NeoGenomics [NEO] Unchanged to Outperform at SVB Leerink
SVB Leerink maintained its NeoGenomics [NEO] rating to the equivalent of Outperform but changed the price target to $60.0 from $50, in a research note dated 2021-01-08. That figure represents around a 12.11% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Needham’s analysts reiterating the shares to […]
